Drug intelligence / Profile preview

orcetidine

Development stage: Preclinical
Lead developer: Self-selected topics (self-funded)
Administration: Intravenous

Overview

Orcetidine is a drug that was investigated in a clinical study for pain management in patients with Acute Respiratory Distress Syndrome (ARDS). It was administered intravenously at a dosage of 2-20 μg/kg/h, with the goal of maintaining a Critical-Care Pain Observation Tool (CPOT) score below 3, indicating its intended role as an analgesic or sedative. The specific mechanism of action and molecular modality of orcetidine are not detailed in the provided context or readily available from general public databases under this name.

Beyond the preview

Go deeper on orcetidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on orcetidine.

Explore the full profile